Email ID
Password
Forgotten your password?
Sign me in automatically next time
Advanced Search
Home
Companies
Patients
Investigators
Trials & Research
Regulatory
Therapeutics
Therapeutics
LATEST NEWS
ICON picked to perform trial for troubled Proellex
25 August 2010
ICON plc has begun its recruitment drive for a Phase I / II trial sponsored by Repros Therapeutics Inc , to find the lowest safe and effective dose of the drug firm's troubled investigative anti-progestin compound, Proellex. The Dublin-headquartered CRO will study the effect on 60 healthy women of ...
Quintiles begins two more early-phase trials...
Quintiles and Icon collaborate on epilepsy trial...
PPD handling Phase I trial for BMS
24 August 2010
Pharmaceutical Product Development Inc is looking for 24 patients for a Phase I trial of Dapagliflozin, an investigational treatment for adult-onset diabetes being developed by Bristol-Myers Squibb in partnership with AstraZeneca . The study will look at the effects of oral doses of the ...
More Phase I trials for Quintiles / AZ partnership
24 August 2010
Continuing its active strategic research partnership with AstraZeneca (AZ), Quintiles Transnational Corp has begun looking for patients for two new Phase I trials for the drug giant. The first trial will study the bioavailability of a single oral dose of AZD9668 compared with an intravenous ...
Parexel recruits for Japanese Cytofab study
23 August 2010
Parexel International Corp is now recruiting patients in Japan for a new Phase II study into the safety and tolerability of a drug developed by AstraZeneca to treat sepsis. The CRO is looking for 20 Japanese patients suffering from severe sepsis or septic shock, who will be given two different ...
>> More Latest News...
FEATURES
Conquering cancer in the developing world; the INDOX approach
21 July 2010
The clinical trials sector in India is growing dramatically and could top $2 billion by 2012. In parallel, the rate of cancer in India is increasing due to ongoing lifestyle changes. Joanne Payne profiles a unique academic oncology network that is working to combat what is often thought of as a ...
Migrating from the middle; finding a space for the niche CRO
16 July 2010
Bigger is not always best, but this certainly seems the case for CROs, as competition increases to supply services to a shrinking number of large pharma companies. Nevertheless, focusing on a single therapeutic niche may be a good business strategy for firms unable to effectively compete and ...
Rare diseases in the Middle East: prospects for CROs
02 July 2010
The treatment of rare diseases in Europe has been significantly enhanced by the EU’s Orphan Drug Regulation and by the raised levels of public awareness, improved by the activities of interest groups, with regard to existence and prevalence of such diseases. As a result, research into drugs aimed ...
Diabetes sector continues to generate immense interest
17 June 2010
Looking at a list of companies carrying out clinical development of new products for treating diabetes is like reading a Who’s Who of the pharmaceutical industry. According to Citeline Drug Intelligence , a total of 116 companies are developing products for the treatment of type 1 or type 2 ...
>> More Features...
PEOPLE
Advanced Clinical names new VP
CRO Advanced Clinical , has named Julie Heneghan as vice-president. Heneghan has been in the outsourcing and staffing solutions industry for more than 20 years. As vice-president, she will be responsible for overseeing the strategic planning and direction of the US Midwest and Eastern division and ...
Outcomes Health strengthens IT team
Outcomes Health Information Solutions , a data abstraction and analytics company working with CROs and pharmaceceutical companies, has named David Jeans as the new vice-president of data management and chief enterprise architect. Jeans is responsible for leading the execution and enhancement of ...
Prism appoints Nigel Brooksby as non-exec chairman
Drug development consultancy Prism Ideas , has appointed Nigel Brooksby , as non-executive chairman. Brooksby has more than 35 years experience in the life sciences industry, culminating in his position as chairman and managing director for Sanofi-Aventis UK and leading the UK's Association of the ...
>> More People...
COMMENTARY
MHRA Guidance; impacts for the central lab
Our quality assurance officer in Europe, Elizabeth Atkin , and I attended the MHRA conference – GCP for Clinical Laboratories – Clinical Pursuits in York, England, at the beginning of the year. The various sessions throughout the day provided comprehensive overviews of how the clinical trials ...
As Scott Reuben faces jail, just how common is fraud in clinical trials?
Last month, the prominent and pioneering anaesthesiologist Scott Reuben , chief of acute pain at Baystate Medical Centre , was sentenced to six months in prison for falsifying the data in, or entirely inventing, dozens of clinical trials. In the end, what caught Reuben was an audit of two papers ...
As wages increase, is China still a good location for clinical trials?
The recent condemnation by Charles River Laboratories ' largest shareholder of that company's proposed acquisition of the leading Chinese CRO, WuXi PharmaTech , raised questions about whether companies are being too optimistic about the potential of China as a location for clinical research and the ...
Publication bias on the agenda again
IQWiG , the German health technology assessment institute, has renewed its call for legislation to make the prospective registration of clinical trials mandatory and to compel trial sponsors to publish the full results of all trials in a results database. The demand comes in a new study, published ...
Decision time: how to take the EDCTP forward
A proverb attributed to the Chinese philosopher Lao Tsu says: give a man a fish and you feed him for a day; teach a man to fish and you feed him for a lifetime. That sentiment could well be applied today to the provision of medicines for diseases that predominantly affect resource-poor countries, ...
Challenges and breakthroughs in IBD
Inflammatory bowel disease is a term used to cover two specific conditions that are both chronic diseases that affect the gastrointestinal tract – Crohn's disease and ulcerative colitis. The main difference between them is the area of the gut that they affect. In Crohn's disease, the inflammation ...
>> More Commentary...
About Us
Getting Started
Subscribe
FREE Trial
Advertise
Awards
White Papers
EVENTS
Clinical trial supply Asia 2010
14 September 2010
Singapore
Children's Medicines Working Party
28 September 2010
London, UK
Drafting and negotiating clinical trials agreements
09 November 2010
London, UK
